[Influence of angiotensin I converting enzyme inhibitors on selected parameters of zinc metabolism].
The aim of the study was to assess the influence of angiotensin converting enzyme inhibitors (ACEI) on zinc metabolism. Thirty one patients (pts) with essential hypertension (EH) were divided into two groups: 1. 16 pts. 6 females (F) and 10 males (M) (age 46.5 +/- 7) who were treated with benazepril (nonsulphydryl ACEI). 2. 15 pts, 6F and 9M (age 45.9 +/- 10.7) receiving captopril (sulphdryl ACEI). Trial was randomized, double-blind. The dose of 10 mg of benazepril administered once daily was compared with 50 mg of captopril once daily. If after 4 weeks of treatment the blood pressure (BP) was adequately controlled (DBP < or = 90 mmHg)), the same treatment was continued for further 4 weeks. In pts with DBP > 90 mmHg after 4 weeks, the dosage of trial medication was doubled and continued for further 4 weeks. Erythrocyte (ZnE) and serum (ZnS) zinc as well as 24 hour urinary zinc excretion (ZnU) and glomerular filtration rate were assessed before starting treatment and after 4 and 8 weeks of ACEI therapy. ZnS significantly lowered and ZnU increased during ACEI therapy whereas ZnE did not change. Up to 4 weeks there were no statistical differences between captopril and benazepril regarding their influence on zinc metabolism. After 8 weeks of therapy ZnS decreased more significantly in captopril group (p < 0.01). Glomerular filtration rate did not significantly change during ACEI therapy. ACEI therapy may influence zinc metabolism.